Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes-Reference-Cited by-同舟云学术

Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes

Published:2022-10-05 Issue:12 Volume:101 Page:2633-2643
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Mathieu Meunier^ORCID,Friedrich Chloé,Ducrot Nicolas,Zannoni Johanna,Sylvie Tondeur,Jerraya Nelly,Rousseaux Sophie,Chuffart Florent,Kosmider Olivier,Karim Zoubida,Park Sophie

Funder

Celgene

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-022-04993-7.pdf

Reference40 articles.

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405

2. Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X (2019) Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev 34:1–15

3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088

4. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465

5. Santini V (2015) Anemia as the main manifestation of myelodysplastic syndromes. Semin Hematol 52:348–356

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid and sustained response to luspatercept and eltrombopag combined treatment in one case of clonal cytopenias of undetermined significance with prior failure to cyclosporin and androgen therapy: a case report;Therapeutic Advances in Hematology;2024-01

2. Clinical decision-making and treatment of myelodysplastic syndromes;Blood;2023-12-28

3. SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process;Frontiers in Oncology;2023-03-17